Plasma Soluble VEGFR-1 Is a Potential Dual Biomarker of Response and Toxicity for Bevacizumab with Chemoradiation in Locally Advanced Rectal Cancer
Open Access
- 18 May 2010
- journal article
- research article
- Published by Oxford University Press (OUP) in The Oncologist
- Vol. 15 (6) , 577-583
Abstract
We explored plasma and urinary concentrations of two members of the vascular endothelial growth factor (VEGF) family and their receptors as potential response and toxicity biomarkers of bevacizumab with neoadjuvant chemoradiation in patients with localized rectal cancer. The concentrations of VEGF, placental growth factor (PlGF), soluble VEGF receptor 1 (sVEGFR-1), and sVEGFR-2 were measured in plasma and urine at baseline and during treatment. Pretreatment values and changes over time were analyzed as potential biomarkers of pathological response to treatment as well as for acute toxicity in patients with locally advanced rectal cancer treated prospectively in 2002–2008 with neoadjuvant bevacizumab, 5-fluorouracil, radiation therapy, and surgery in a phase I/II trial. Of all biomarkers, pretreatment plasma sVEGFR-1—an endogenous blocker of VEGF and PlGF, and a factor linked with “vascular normalization”—was associated with both primary tumor regression and the development of adverse events after neoadjuvant bevacizumab and chemoradiation. Based on the findings in this exploratory study, we propose that plasma sVEGFR-1 should be further studied as a potential biomarker to stratify patients in future studies of bevacizumab and/or cytotoxics in the neoadjuvant setting.Keywords
Funding Information
- NIH (R21-CA99237, P01-CA80124, R01-CA115767, R01-CA85140, R01-CA126642)
- Federal Share/NCI Proton Beam Program Income
- National Foundation for Cancer Research
This publication has 25 references indexed in Scilit:
- Phase II Trial of Neoadjuvant Bevacizumab, Capecitabine, and Radiotherapy for Locally Advanced Rectal CancerInternational Journal of Radiation Oncology - Biology - Physics (IJROBP), 2010
- Preoperative versus Postoperative Chemoradiotherapy for Rectal CancerNew England Journal of Medicine, 2004
- Bevacizumab plus Irinotecan, Fluorouracil, and Leucovorin for Metastatic Colorectal CancerNew England Journal of Medicine, 2004
- Urinary VEGF and MMP Levels As Predictive Markers of 1-Year Progression-Free Survival in Cancer Patients Treated With Radiation Therapy: A Longitudinal Study of Protein Kinetics Throughout Tumor Progression and TherapyJournal of Clinical Oncology, 2004
- Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancerNature Medicine, 2004
- The biology of VEGF and its receptorsNature Medicine, 2003
- Vascular Permeability Factor/Vascular Endothelial Growth Factor: A Critical Cytokine in Tumor Angiogenesis and a Potential Target for Diagnosis and TherapyJournal of Clinical Oncology, 2002
- Herceptin acts as an anti-angiogenic cocktailNature, 2002
- Pathologic assessment of tumor regression after preoperative chemoradiotherapy of esophageal carcinoma. Clinicopathologic correlationsCancer, 1994
- Flexible regression models with cubic splinesStatistics in Medicine, 1989